IVERMECTIN AS ADJUVANT TO HYDROXYCHOLOROQUINE IN PATIENTS RESISTANT TO STANDARD TREATMENT FOR SARS-CoV-2: RESULTS OF AN OPEN-LABEL RANDOMIZED CLINICAL STUDY
| Autor: | Naveen Kishoria, B.S Parihar, Rimple Jeet Kaur, Veeram Parmar, S. L. Mathur, Harish Agarwal, Somil Verma |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty medicine.diagnostic_test business.industry viruses Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Standard treatment medicine.medical_treatment 030106 microbiology virus diseases medicine.disease Gastroenterology respiratory tract diseases 03 medical and health sciences 030104 developmental biology Ivermectin Internal medicine Biopsy medicine Carcinoma Papilloma Open label business Adjuvant medicine.drug |
| Zdroj: | PARIPEX INDIAN JOURNAL OF RESEARCH. :1-4 |
| DOI: | 10.36106/paripex/4801859 |
| Popis: | A cluster of pneumonia cases of unknown etiology was reported from the city of Wuhan, in the Hubei province of China, in December 2019. A novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the causative agent of the disease which was subsequently termed as the coronavirus disease (COVID-19) by the World Health Organization (WHO). SARS-CoV-2 mainly affects the lower res-piratory tract and manifests as pneumonia in humans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|